Current Report Filing (8-k)
June 14 2018 - 6:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
|
June
12, 2018
|
Interpace
Diagnostics Group, Inc.
(Exact
name of registrant as specified in charter)
DELAWARE
|
|
000-24249
|
|
22-2919486
|
(State
or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
file number)
|
|
(I.R.S.
Employer
Identification Number)
|
Morris
Corporate Center 1, Building C
300
Interpace Parkway
Parsippany,
NJ 07054
(Address
of principal executive offices; zip code)
(855)-776-6419
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
June 12, 2018, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals
were voted on and approved by the Company’s stockholders at the Annual Meeting with the stockholders having voted as set
forth below:
Proposal
1:
|
To
elect one Class II member of the Board of Directors of the Company, who will serve for a term of three years.
|
|
|
For
|
|
|
Withhold
|
|
|
Broker Non-Vote
|
|
Dr. Felice Schnoll-Sussman
|
|
|
3,539,614
|
|
|
|
174,162
|
|
|
|
18,259,812
|
|
Proposal
2:
|
To
ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2018.
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non-Vote
|
|
|
18,164,342
|
|
|
|
1,823,935
|
|
|
|
1,985,311
|
|
|
|
0
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Interpace
Diagnostics Group, Inc.
|
|
|
|
Date:
June 14, 2018
|
By:
|
/s/
Jack E. Stover
|
|
|
Jack
E. Stover
|
|
|
Chief
Executive Officer
|
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024